EUVIMEDEUVIMED entdecken
Crossref

1712-P: Benefits of HR17031 vs. Insulin Glargine (iGlar) in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) and Metformin

LIMING CHEN, QIUMEI ZHANG, NIANRONG MI, JIE ZHANG, WEN HU, GUIPING LI, TAO LEI, ZI YE, QIANNAN ZHOU, TIANXING XU, XINFENG YANG

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1712-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von LIMING CHEN und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: To assess efficacy and safety of HR17031, a fixed-ratio combination of BI analogue (insulin sudelidec) and GLP-1 receptor agonist (noiiglutide), vs iGlar in pts with T2D uncontrolled on BI plus metformin, with or without another oral antidiabetic drug (OAD).

Methods

In this randomized, multicenter, treat-to-target, phase 3 trial, 393 Chinese adults with T2D (HbA1c 7.5%-10.5%; previous BI + metformin ± another OAD) were randomized (1:1) to HR17031 (n = 197) or iGlar (n = 196) for 26 weeks, along with metformin. Primary outcome was HbA1c change at 26 weeks.

Results

At 26 weeks, superiority was confirmed for HR17031 over iGlar in HbA1c change (-1.53% vs -0.25%, difference = -1.29%; Fig 1). HR17031 was superior to iGlar in the proportion of pts reaching HbA1c < 7.0% (48.7% vs 10.7%), HbA1c ≤ 6.5% (34.0% vs 4.1%), and HbA1c < 7.0% without weight gain (29.4% vs 3.6%). HR17031 led to weight loss in contrast to iGlar (-0.06 vs 1.35 kg). Insulin dose of HR17031 was lower than iGlar (29.9 vs 36.6 U/d). Greater reduction in FPG was reached with HR17031 than iGlar (-2.05 vs -0.68 mmol/L). All the above results were statistically significant (all P < 0.0001). Incidence of hypoglycemia was 32.3% with HR17031 and 53.3% with iGlar. No level 3 hypoglycemia was reported. No unexpected safety issues occurred.

Conclusion

Compared to iGlar, HR17031 is effective and well-tolerated in pts with T2D uncontrolled on BI and OAD(s). Disclosure L. Chen: Research Support; Current; AstraZeneca, Lilly, Gan & Lee Pharmaceuticals, Novo Nordisk, Sanofi. Q. Zhang: None. N. Mi: None. J. Zhang: None. W. Hu: None. G. Li: None. T. Lei: None. Z. Ye: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Q. Zhou: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. T. Xu: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. X. Yang: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Funding Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Zitieren

APA

CHEN, L., ZHANG, Q., MI, N., ZHANG, J., HU, W., LI, G., LEI, T., YE, Z., ZHOU, Q., XU, T., & YANG, X. (2026). 1712-P: Benefits of HR17031 vs. Insulin Glargine (iGlar) in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) and Metformin. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1712-p

Vancouver

CHEN L, ZHANG Q, MI N, ZHANG J, HU W, LI G, et al. 1712-P: Benefits of HR17031 vs. Insulin Glargine (iGlar) in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) and Metformin. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1712-p

BibTeX
@article{CHEN2026,
  author = {CHEN, LIMING and ZHANG, QIUMEI and MI, NIANRONG and ZHANG, JIE and HU, WEN and LI, GUIPING and LEI, TAO and YE, ZI and ZHOU, QIANNAN and XU, TIANXING and YANG, XINFENG},
  title = {1712-P: Benefits of HR17031 vs. Insulin Glargine (iGlar) in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) and Metformin},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1712-p}
}
Kostenlos starten →